ClinicalTrials.gg
CompletedNCT01016483Updated Jul 13, 2017Results posted

Trial of Gemcitabine With or Without MSC1936369B in Pancreatic Cancer

A Phase 1/2 interventional study of Pimasertib and Gemcitabine in Pancreatic Adenocarcinoma, sponsored by EMD Serono. Completed at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-07-13.

Sponsored by EMD Serono (part of Merck KGaA, Darmstadt, Germany) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
141
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The research trial is testing the experimental treatment MSC1936369B in combination with Gemcitabine, in subjects with metastatic pancreatic adenocarcinoma. The study will be run in two parts:

Safety Run-In: Will determine the Maximum Tolerated Dose (MTD) and the recommended Phase II dose of MSC1936369B, when combined with gemcitabine, in subjects with metastatic pancreatic adenocarcinoma.

Phase II: Will assess the anti-tumor activity of MSC1936369B combined with gemcitabine compared to gemcitabine alone as first line treatment in subjects with metastatic pancreatic adenocarcinoma.

02

Conditions studied

  • Pancreatic Adenocarcinoma

Keywords

  • MEK inhibitor
  • cancer
  • pancreatic Adenocarcinoma
  • metastatic
  • chemo-naive
  • phase II
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 141 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

EMD Serono is the lead sponsor of 91 studies on the registry; none are open to participants now.

First submitted after EMD Serono became part of Merck KGaA, Darmstadt, Germany.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject has provided signed . Fully understands requirements of the trial and willing to comply with all trial visits and assessments.
  2. or cytologically confirmed adenocarcinoma of the pancreas and availability of tumor sample.
  3. Evidence of disease (not necessarily ). Complete tumor assessment including chest X ray, CT scan of abdomen and other scans as necessary to document all sites of disease performed within 28 days prior to trial entry/randomization.
  4. Age ≥ 18 years.
  5. Women of must have a negative blood pregnancy test at the screening visit. For the purposes of this trial, women of childbearing potential is defined as: "All female subjects after puberty unless they are for at least two years, are surgically sterile or are sexually inactive."
  6. Female subjects of childbearing potential and male subjects with female partners of childbearing potential must be willing to avoid pregnancy by using an adequate method of for 2 weeks prior to screening, during and four weeks after the last dose of trial medication. Adequate contraception is defined as two barrier methods, or one barrier method with a spermicide, or intrauterine device. The use of hormonal contraceptives should be avoided in female subjects of childbearing potential due to a possible drug-drug interaction.

Exclusion criteria

Exclusion Criteria:

  1. Bone marrow impairment as evidenced by less (\<) 9.0 gram per deciliter (g/dL), \< 1.5 x 10\^9/ liter (L), \< 100 x 10\^9/L.
  2. Renal impairment as evidenced by serum creatinine > 1.5 x (ULN), and/or calculated \< 60 mL/min.
  3. Liver function abnormality as defined by total > 1.5 x ULN, or / alanine aminotransferase (AST/ALT) > 2.5 x ULN, for subjects with liver involvement AST/ALT > 5 x ULN.
  4. Serum calcium > 1 x ULN.
  5. History of central nervous system (CNS) , unless subject has been previously treated for , is stable by CT scan without evidence of cerebral edema, and has no requirements for or anticonvulsants.
  6. Performance Status (ECOG PS) greater than 1.
  7. Significant cardiac conduction abnormalities, including corrected for heart rate (QTc) prolongation of > 480 milliseconds (ms) and/or pacemaker.
  8. Retinal degenerative disease (hereditary retinal degeneration or age-related macular degeneration), history of uveitis or history of retinal vein occlusion.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
141 participants (actual)

Study arms

  • Experimental
    Safety Run-in Part: Regimen 1

    Subjects will receive pimasertib capsule orally once daily (qd) doses of 15, 30, 45, 68, 90, and 120 milligram (mg) on Day 1, 2, 3, 4, 5, 8, 9, 10, 11, 12, 15,16, 17, 18, 19, 22, 23, 24, 25, 26 and gemcitabine 1000 milligram per square meter (mg/m\^2) intravenous (IV) infusion for 30 minutes on Days 1, 8, 15, 22, 29, 36, and 43 followed by a 1-week rest (1 Cycle = 8 weeks).

    Drug: Pimasertib · Drug: Gemcitabine

  • Experimental
    Safety Run-in Part: Regimen 2

    Subjects will receive pimasertib capsule orally twice daily (bid) doses of 60 and 75 mg continuously for a 28-day cycle and gemcitabine 1000 mg/m\^2 intravenous (IV) infusion for 30 minutes on Days 1, 8, 15, 22, 29, 36, and 43 followed by a 1-week rest (1 Cycle = 8 weeks) (bid - continuous regimen).

    Drug: Pimasertib · Drug: Gemcitabine

  • Active comparator
    Phase II: Arm 1 (Gemcitabine + Placebo)

    Subjects will receive gemcitabine 1000 mg/m\^2 IV infusion on for 30 minutes on Day 1, 8, 15, 22, 29, 36, and 43 followed by a 1-week rest (Cycle 1) then on Days 1, 8, and 15 of a 28-day cycle and placebo matched to pimasertib orally bid - continuous regimen.

    Drug: Gemcitabine · Drug: Placebo

  • Experimental
    Phase II: Arm 2 (Gemcitabine + Pimasertib)

    Subjects will receive gemcitabine 1000 mg/m\^2 IV infusion for 30 minutes on Day 1, 8, 15, 22, 29, 36, and 43 followed by a 1-week rest (Cycle 1) then on Days 1, 8, and 15 of a 28-day cycle and pimasertib capsule orally bid - continuous regimen.

    Drug: Pimasertib · Drug: Gemcitabine

Interventions

06

What researchers measure

Primary outcomes

  1. Safety Run-In Part: Number of Subjects With Dose Limiting Toxicities (DLTs)

    DLT using the National Cancer Institute Common Terminology Criteria for Adverse Events(CTCAE) v3.0,was defined as any of the following toxicities at any dose level and judged to be possibly or probably related to trial medication by the Investigator and/or the Sponsor and relevant for the combination treatment: Grade 3/more non-hematological toxicity excluding: Subjects with liver involvement: Grade 4 asymptomatic increases in liver function tests and subject without liver involvement: Grade 3 asymptomatic increases in liver function tests reversible within 7 days. Grade 3 vomiting encountered despite adequate therapy. Grade 3 diarrhea encountered despite adequate anti diarrhea therapy. Grade 4 neutropenia greater (\>) 5 days duration or febrile neutropenia lasting for more than 1 day. Grade 4 thrombocytopenia \> 1 day/Grade 3 with bleeding. Grade 4 anemia: Any treatment delay \> 2 weeks due to drug-related adverse effects.

    Time frame: Up to 28 days in Cycle 1

  2. Phase II: Progression-Free Survival (PFS) Time

    PFS was defined as the time from randomization to the first documentation of objective tumor progression (Complete Response (CR): Disappearance of all target lesions, Partial Response (PR): At least 30% decrease in the sum of the longest diameter of target lesions, taking as reference the sum of the longest diameter at baseline, Progressive Disease (PD): At least 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum of the longest diameter recorded since treatment started, or the appearance of 1 or more new lesions and stable disease: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of the longest diameter since treatment started) or to death due to any cause, whichever occurred first. PFS calculated as (Months) = Date of first PD or death or censoring date minus date of randomization plus 1) divided by 30.4375.

    Time frame: From the time of randomization to every 8 weeks up to end of treatment (EOT) (6 years)

Secondary outcomes

  1. Safety Run-In Part: Number of Subjects With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Leading to Permanent Treatment Discontinuation

    An adverse event (AE) was any untoward medical occurrence in a subjects who received study drug without regard to possibility of causal relationship. An serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. All AEs (serious and non-serious) except AEs recorded with an onset date prior to the first day of drug administration unless a worsening of the event was recorded after the first dosing date, in which case the event was counted as a TEAE. TEAEs include both SAEs and non-SAEs.

    Time frame: From the first dose of study drug administration until EOT (6 years)

  2. Safety Run-In Part: Maximum Concentration (Cmax) of Pimasertib (MSC1936369B), Gemcitabine (dFdC), and Gemcitabine Inactive Metabolite 2',2'-Difluorodeoxyuridine (dFdU) for Regimen 1

    Time frame: 0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1, 22 of Cycle 1

  3. Safety Run-In Part: Time to Reach Maximum Concentration (Tmax) of Pimasertib (MSC1936369B), Gemcitabine (dFdC), and Gemcitabine Inactive Metabolite 2',2'-Difluorodeoxyuridine (dFdU): Regimen 1

    Time frame: 0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1, 22 of Cycle 1

  4. Safety Run-In Part: Time to Reach Apparent Terminal Half-Life (t1/2) of Pimasertib (MSC1936369B), Gemcitabine (dFdC), and Gemcitabine Inactive Metabolite 2',2'-Difluorodeoxyuridine (dFdU): Regimen 1

    Plasma decay half-life was the time measured for the plasma concentration to decrease by one half.

    Time frame: 0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1, 22 of Cycle 1

  5. Safety Run-In Part: Area Under Curve (AUC: 0 to Infinity) of Pimasertib (MSC1936369B), Gemcitabine (dFdC), and Gemcitabine Inactive Metabolite 2',2'-Difluorodeoxyuridine (dFdU): Regimen 1

    AUC:0 to infinity was a measure of the serum concentration of the drug over time. It was used to characterize drug absorption.

    Time frame: 0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1 of Cycle 1 for MSC1936369B, 0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1, 22 of Cycle 1 for Gemcitabine

  6. Safety Run-In Part: Apparent Oral Clearance (CL/f) of Pimasertib (MSC1936369B): Regimen 1

    Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) was influenced by the fraction of the dose absorbed.

    Time frame: 0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1, 22 of Cycle 1

  7. Safety Run-In Part: Total Clearance (CL) of Gemcitabine: Regimen 1

    Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.

    Time frame: 0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1, 22 of Cycle 1

  8. Safety Run-In Part: Oral Volume of Distribution (V/f) of Pimasertib (MSC1936369B): Regimen 1

    Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.

    Time frame: 0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1, 22 of Cycle 1

  9. Safety Run-In Part: Apparent Volume of Distribution (V) of Gemcitabine: Regimen 1

    Apparent volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.

    Time frame: 0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1, 22 of Cycle 1

  10. Safety Run-In Part: Levels of Pharmacodynamic (Pd) Markers (Phosphorylated- Extracellular Signal-Regulated Kinase (ERK) in Peripheral Blood Mononuclear Cells [PBMCs]): Regimen 1

    ERK phosphoprotein in peripheral blood monocytes (PBMCs) was analyzed from blood samples of all subjects in the SAF analysis set (safety-run part) only.

    Time frame: pre-dose on Day 1, 2, 22 of Cycle 1; post-dose on Day 1, 22 of Cycle 1

  11. Safety Run-In Part: Maximum Concentration (Cmax) of Pimasertib (MSC1936369B), Gemcitabine (dFdC), Gemcitabine Inactive Metabolite 2',2'-Difluorodeoxyuridine (dFdU): Regimen 2

    Time frame: 0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1, 22 of Cycle 1

  12. Safety Run-In Part: Area Under Curve (AUC:0 to Infinity) of Pimasertib (MSC1936369B), Gemcitabine (dFdC), and Gemcitabine Inactive Metabolite 2',2'-Difluorodeoxyuridine (dFdU) Regimen 2

    AUC:0 to infinity is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption.

    Time frame: 0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1 of Cycle 1 for MSC1936369B, 0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1, 22 of Cycle 1 for Gemcitabine

  13. Safety Run-In Part: Time to Reach Maximum Concentration (Tmax) of Pimasertib (MSC1936369B), Gemcitabine (dFdC), and Gemcitabine Inactive Metabolite 2',2'-Difluorodeoxyuridine (dFdU): Regimen 2

    Time frame: 0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1, 22 of Cycle 1

  14. Safety Run-In Part: Time to Reach Apparent Terminal Half-Life (t1/2) of Pimasertib (MSC1936369B), Gemcitabine (dFdC), and Gemcitabine Inactive Metabolite 2',2'-Difluorodeoxyuridine (dFdU): Regimen 2

    Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

    Time frame: 0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1, 22 of Cycle 1

  15. Safety Run-In Part: Apparent Oral Clearance (CL/f) of Pimasertib (MSC1936369B): Regimen 2

    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.

    Time frame: 0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1, 22 of Cycle 1

  16. Safety Run-In Part: Total Clearance (CL) of Gemcitabine: Regimen 2

    Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.

    Time frame: 0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1, 22 of Cycle 1

  17. Safety Run-In Part: Apparent Volume of Distribution (V) of Gemcitabine: Regimen 2

    Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.

    Time frame: 0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1, 22 of Cycle 1

  18. Safety Run-In Part: Oral Volume of Distribution (V/f) of Pimasertib (MSC1936369B): Regimen 2

    Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.

    Time frame: 0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1, 22 of Cycle 1

  19. Safety Run-In Part: Levels of Pharmacodynamic (Pd) Markers (Phosphorylated- Extracellular Signal-Regulated Kinase (ERK) in Peripheral Blood Mononuclear Cells [PBMCs]): Regimen 2

    ERK phosphoprotein in peripheral blood monocytes (PBMCs) was analyzed from blood samples of all subjects in the SAF analysis set (safety-run part) only.

    Time frame: pre-dose on Day 1, 2, 22 of Cycle 1; post-dose on Day 1, 22 of Cycle 1

  20. Phase II: Number of Subjects With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Leading to Permanent Treatment Discontinuation

    An AE was any untoward medical occurrence in a subject who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. All AEs (serious and non-serious) except AEs recorded with an onset date prior to the first day of drug administration unless a worsening of the event was recorded after the first dosing date, in which case the event was counted as a TEAE. TEAEs include both SAEs and non-SAEs.

    Time frame: From the first dose of study drug administration until EOT (6 years)

  21. Phase II: Percentage of Subjects With Best Overall Response (BOR)

    Best overall response was defined as the presence of at least one complete response (CR), partial response (PR) or Stable Disease (SD) (using RECIST v1.0) during treatment. CR: Disappearance of all target lesions, PR: At least 30% decrease in the sum of the longest diameter of target lesions, taking as reference the sum of the longest diameter at baseline and SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of the longest diameter since treatment started.

    Time frame: Baseline, every 8 weeks up to end of treatment (EOT i.e. 6 years)

  22. Phase II: Percentage of Subjects With Clinical Benefit

    Clinical Benefit was defined as the presence of at least one CR, PR or Stable Disease (SD) (using RECIST v1.0) during treatment. CR: Disappearance of all target lesions, PR: At least 30% decrease in the sum of the longest diameter of target lesions, taking as reference the sum of the longest diameter at baseline and SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of the longest diameter since treatment started.

    Time frame: Baseline, every 8 weeks up to end of treatment (EOT i.e. 6 years)

  23. Phase II: Time to Progression (TTP)

    Time to progression (TTP) is defined as the time (in months) from the randomization date to the date of progression prior to the start of any subsequent therapy for the primary disease, as reported and documented by the Investigator (i.e. radiological progression per RECIST).

    Time frame: From randomization every 8 weeks up to EOT (6 years)

  24. Phase II: Overall Survival (OS) Time

    Overall survival (OS) time is defined as the time (in months) from randomization to death.

    Time frame: Baseline, every 8 weeks up to EOT (6 years)

  25. Phase II: Absorption Rate Constant (ka) of Pimasertib (MSC1936369B)

    Time frame: Baseline, every 8 weeks up to EOT (6 years)

  26. Phase II: Clearance From Central Compartment (CL/f) and Intercompartmental Clearance (Q/f) of Pimasertib (MSC1936369B)

    Time frame: Baseline, every 8 weeks up to EOT (6 years)

  27. Phase II: Volume of Central Compartment (V1/f) and Volume of Peripheral Compartment (V2/f) of Pimasertib (MSC1936369B)

    Time frame: Baseline, every 8 weeks up to EOT (6 years)

07

Results

Posted Jun 23, 2017

Participant flow

First/last subject (informed consent): Nov 2009/Jul 2013. Clinical data cut off: Dec 2013, Study completion date: April 2015

Safety Run-in Part
Participant flow — Safety Run-in Part
MilestoneSafety Run-in Part: Regimen 1Safety Run-in Part: Regimen 2Phase II: Arm 1 (Gemcitabine + Placebo)Phase II: Arm 2 (Gemcitabine + Pimasertib)
Started272600
Completed272600
Not completed0000
Phase II
Participant flow — Phase II
MilestoneSafety Run-in Part: Regimen 1Safety Run-in Part: Regimen 2Phase II: Arm 1 (Gemcitabine + Placebo)Phase II: Arm 2 (Gemcitabine + Pimasertib)
Started004444
Treated (safety analysis set [saf])004245
Completed004444
Not completed0000

Outcome measures

PrimarySafety Run-In Part: Number of Subjects With Dose Limiting Toxicities (DLTs)

DLT using the National Cancer Institute Common Terminology Criteria for Adverse Events(CTCAE) v3.0,was defined as any of the following toxicities at any dose level and judged to be possibly or probably related to trial medication by the Investigator and/or the Sponsor and relevant for the combination treatment: Grade 3/more non-hematological toxicity excluding: Subjects with liver involvement: Grade 4 asymptomatic increases in liver function tests and subject without liver involvement: Grade 3 asymptomatic increases in liver function tests reversible within 7 days. Grade 3 vomiting encountered despite adequate therapy. Grade 3 diarrhea encountered despite adequate anti diarrhea therapy. Grade 4 neutropenia greater (\>) 5 days duration or febrile neutropenia lasting for more than 1 day. Grade 4 thrombocytopenia \> 1 day/Grade 3 with bleeding. Grade 4 anemia: Any treatment delay \> 2 weeks due to drug-related adverse effects.

Time frame:
Up to 28 days in Cycle 1
Reported as:
Number · subjects
Safety Run-In Part: Number of Subjects With Dose Limiting Toxicities (DLTs)
subjectsSafety Run-in Part Regimen 1: 15 mgSafety Run-in Part Regimen 1: 30 mgSafety Run-in Part Regimen 1: 45 mgSafety Run-in Part Regimen 1: 68 mgSafety Run-in Part Regimen 1: 90 mgSafety Run-in Part Regimen 1: 120 mgSafety Run-in Part Regimen 2: 60 mgSafety Run-in Part Regimen 2: 75 mg
Safety Run-In Part: Number of Subjects With Dose Limiting Toxicities (DLTs)00000012
PrimaryPhase II: Progression-Free Survival (PFS) Time

PFS was defined as the time from randomization to the first documentation of objective tumor progression (Complete Response (CR): Disappearance of all target lesions, Partial Response (PR): At least 30% decrease in the sum of the longest diameter of target lesions, taking as reference the sum of the longest diameter at baseline, Progressive Disease (PD): At least 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum of the longest diameter recorded since treatment started, or the appearance of 1 or more new lesions and stable disease: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of the longest diameter since treatment started) or to death due to any cause, whichever occurred first. PFS calculated as (Months) = Date of first PD or death or censoring date minus date of randomization plus 1) divided by 30.4375.

Time frame:
From the time of randomization to every 8 weeks up to end of treatment (EOT) (6 years)
Reported as:
Median · months
Phase II: Progression-Free Survival (PFS) Time
monthsPhase II: Arm 1Phase II: Arm 2
Phase II: Progression-Free Survival (PFS) Time2.83 (1.77 to 3.88)3.75 (2.63 to 5.09)
SecondarySafety Run-In Part: Number of Subjects With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Leading to Permanent Treatment Discontinuation

An adverse event (AE) was any untoward medical occurrence in a subjects who received study drug without regard to possibility of causal relationship. An serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. All AEs (serious and non-serious) except AEs recorded with an onset date prior to the first day of drug administration unless a worsening of the event was recorded after the first dosing date, in which case the event was counted as a TEAE. TEAEs include both SAEs and non-SAEs.

Time frame:
From the first dose of study drug administration until EOT (6 years)
Reported as:
Number · subjects
Safety Run-In Part: Number of Subjects With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Leading to Permanent Treatment Discontinuation
subjectsSafety Run-in Part: Regimen 1Safety Run-in Part: Regimen 2
TEAEs2726
Serious TEAEs1820
Permanent treatment discontinuation of pimasertib1216
Permanent treatment discontinuation of gemcitabine1415
SecondarySafety Run-In Part: Maximum Concentration (Cmax) of Pimasertib (MSC1936369B), Gemcitabine (dFdC), and Gemcitabine Inactive Metabolite 2',2'-Difluorodeoxyuridine (dFdU) for Regimen 1
Time frame:
0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1, 22 of Cycle 1
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Safety Run-In Part: Maximum Concentration (Cmax) of Pimasertib (MSC1936369B), Gemcitabine (dFdC), and Gemcitabine Inactive Metabolite 2',2'-Difluorodeoxyuridine (dFdU) for Regimen 1
nanogram per milliliter (ng/mL)Regimen 1: 15 mgRegimen 1: 30 mgRegimen 1: 45 mgRegimen 1: 68 mgRegimen 1: 90 mgRegimen 1: 120 mg
MSC1936369B on Days 1 (n=4,3,3,3,3,11)32.3 ± 107.5131.0 ± 32.9205.8 ± 30.0151.3 ± 40.1485.3 ± 58.7484.3 ± 39.8
MSC1936369B on Days 22 (n= 3,3,3,2,3,10)29.6 ± 39.8174.2 ± 29.6261.8 ± 52.0212.5 ± 16.9409.1 ± 44.1252.9 ± 477.0
Gemcitabine (dFdC) on Day 1 (n=4,3,3,3,3,11)69540.5 ± 1729.421207.3 ± 21.017759.9 ± 34.129762.1 ± 76.715606.3 ± 23.123880.7 ± 83.8
Gemcitabine (dFdC) on Day 22 (n= 2,3,3,2,3,9)24115.8 ± 71.911799.7 ± 167.7181.9 ± 39158542.7163196.2 ± 3183.3669.5 ± 327882592323207.2 ± 99.5
Metabolite (dFdU) on Day 1 (n= 4,3,3,3,3,11)29359.8 ± 8.533171.6 ± 21.234868.9 ± 12.833804.4 ± 16.737786.4 ± 13.634038.7 ± 29.7
Metabolite (dFdU) on Day 22 (n= 2,3,3,2,3,10)29677.6 ± 3.038265.2 ± 54.310569.2 ± 449.232869.2 ± 8.717135.0 ± 227.521077.5 ± 179.5
SecondarySafety Run-In Part: Time to Reach Maximum Concentration (Tmax) of Pimasertib (MSC1936369B), Gemcitabine (dFdC), and Gemcitabine Inactive Metabolite 2',2'-Difluorodeoxyuridine (dFdU): Regimen 1
Time frame:
0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1, 22 of Cycle 1
Reported as:
Median · hours
Safety Run-In Part: Time to Reach Maximum Concentration (Tmax) of Pimasertib (MSC1936369B), Gemcitabine (dFdC), and Gemcitabine Inactive Metabolite 2',2'-Difluorodeoxyuridine (dFdU): Regimen 1
hoursRegimen 1: 15 mgRegimen 1: 30 mgRegimen 1: 45 mgRegimen 1: 68 mgRegimen 1: 90 mgRegimen 1: 120 mg
Tmax: MSC1936369B on Day 1 (n= 4,3,3,3,3,11)1.250 (1.00 to 1.50)1.000 (1.00 to 2.50)1.533 (1.00 to 2.00)2.000 (0.67 to 8.00)1.083 (1.00 to 2.00)1.500 (0.50 to 4.00)
Tmax: MSC1936369B on Day 22 (n= 3,3,3 2,3,10)2.017 (1.28 to 4.00)1.000 (0.50 to 2.50)1.000 (0.50 to 1.58)1.750 (1.00 to 2.50)1.500 (1.00 to 1.75)2.000 (0.83 to 8.00)
Tmax: Gemcitabine (dFdC) on Day 1 (n=4,3,3,3,3,11)0.38 (0.25 to 0.50)0.50 (0.25 to 0.50)0.25 (0.25 to 0.50)0.25 (0.25 to 1.17)0.25 (0.25 to 0.38)0.27 (0.25 to 0.75)
Tmax: Gemcitabine (dFdC) on Day 22 (n=2,3,3,2,3,9)0.42 (0.33 to 0.50)0.50 (0.50 to 1.58)0.53 (0.25 to 2.00)1.04 (1.00 to 1.08)0.25 (0.23 to 24.00)0.50 (0.25 to 0.75)
Tmax: Metabolite (dFdU) on Day 1 (n=4,3,3,3,3,11)0.64 (0.50 to 1.00)0.50 (0.50 to 0.75)0.50 (0.50 to 0.77)0.75 (0.67 to 1.00)0.50 (0.38 to 0.50)0.50 (0.25 to 0.75)
Tmax: Metabolite (dFdU) on Day 22 (n=2,3,3,2,3,100.54 (0.33 to 0.75)0.75 (0.50 to 1.58)1.00 (0.73 to 2.00)0.67 (0.33 to 1.00)0.75 (0.50 to 24.00)0.75 (0.00 to 1.00)
SecondarySafety Run-In Part: Time to Reach Apparent Terminal Half-Life (t1/2) of Pimasertib (MSC1936369B), Gemcitabine (dFdC), and Gemcitabine Inactive Metabolite 2',2'-Difluorodeoxyuridine (dFdU): Regimen 1

Plasma decay half-life was the time measured for the plasma concentration to decrease by one half.

Time frame:
0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1, 22 of Cycle 1
Reported as:
Median · hours
Safety Run-In Part: Time to Reach Apparent Terminal Half-Life (t1/2) of Pimasertib (MSC1936369B), Gemcitabine (dFdC), and Gemcitabine Inactive Metabolite 2',2'-Difluorodeoxyuridine (dFdU): Regimen 1
hoursRegimen 1: 15 mgRegimen 1: 30 mgRegimen 1: 45 mgRegimen 1: 68 mgRegimen 1: 90 mgRegimen 1: 120 mg
t1/2: MSC1936369B on Day 1 (n=4,3,3,2,3,11)4.008 (2.539 to 6.131)3.807 (3.373 to 6.648)3.833 (3.612 to 6.477)4.232 (3.382 to 5.083)5.036 (4.361 to 5.120)4.580 (3.394 to 6.938)
t1/2: MSC1936369B on Day 22 (n=2,2,3,2,3,8)8.660 (4.709 to 12.61)6.100 (4.878 to 7.322)3.254 (3.048 to 6.999)5.744 (3.829 to 7.658)3.162 (2.903 to 6.341)4.825 (2.829 to 8.642)
t1/2: Gemcitabine (dFdC) on Day 1 (n=4,3,3,3,3,11)4.274 (2.100 to 7.519)2.461 (1.239 to 6.821)2.421 (0.7070 to 5.709)5.327 (5.148 to 5.338)8.940 (5.565 to 9.982)6.242 (0.8913 to 11.90)
t1/2: Gemcitabine (dFdC) on Day 22 (n=2,2,1,2,2,9)7.449 (6.032 to 8.866)4.553 (2.403 to 6.702)0.9152 (0.9152 to 0.9152)4.493 (2.721 to 6.266)8.213 (6.665 to 9.762)4.680 (0.8685 to 8.490)
t1/2: Metabolite (dFdU) on Day 1 (n=4,3,3,3,3,11)8.956 (8.129 to 14.68)10.49 (4.336 to 10.70)9.836 (9.383 to 14.69)11.52 (9.344 to 12.36)8.349 (7.191 to 9.551)10.93 (8.802 to 15.48)
t1/2: Metabolite (dFdU) on Day 22(n=2,2,2,2,2,10)7.731 (6.978 to 8.483)8.925 (8.299 to 9.552)8.843 (5.427 to 12.26)11.14 (9.119 to 13.17)10.21 (6.782 to 13.64)12.17 (3.468 to 211.2)
SecondarySafety Run-In Part: Area Under Curve (AUC: 0 to Infinity) of Pimasertib (MSC1936369B), Gemcitabine (dFdC), and Gemcitabine Inactive Metabolite 2',2'-Difluorodeoxyuridine (dFdU): Regimen 1

AUC:0 to infinity was a measure of the serum concentration of the drug over time. It was used to characterize drug absorption.

Time frame:
0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1 of Cycle 1 for MSC1936369B, 0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1, 22 of Cycle 1 for Gemcitabine
Reported as:
Geometric mean · hour*nanogram per milliliter (h*ng/mL)
Safety Run-In Part: Area Under Curve (AUC: 0 to Infinity) of Pimasertib (MSC1936369B), Gemcitabine (dFdC), and Gemcitabine Inactive Metabolite 2',2'-Difluorodeoxyuridine (dFdU): Regimen 1
hour*nanogram per milliliter (h*ng/mL)Regimen 1:15 mgRegimen 1: 30 mgRegimen 1: 45 mgRegimen 1: 68 mgRegimen 1: 90 mgRegimen1: 120 mg
AUC: MSC1936369B on Day 1 (n=4,3,3,3,3,11)162.8 ± 25.3516.3 ± 32.9881.1 ± 37.1774.8 ± 58.91729.9 ± 32.32175.1 ± 53.0
AUC: Gemcitabine (dFdC) on Day 1(n=4,3,3,3,3,11)29536.1 ± 473.413536.5 ± 40.410053.3 ± 24.618956.0 ± 37.28178.4 ± 28.711680.1 ± 59.0
AUC: Gemcitabine (dFdC) on Day 22(n=2,2,1,2,2,9)10828.0 ± 93.812019.6 ± 29.59093.2 ± NA76448.7 ± 466.69604.8 ± 11.910598.0 ± 66.7
AUC: Metabolite (dFdU) on Day 1 (n=4,3,3,3,3,11)245795.5 ± 10.8228032.9 ± 27.6276968.3 ± 28.9259816.2 ± 9.2239902.9 ± 27.1240293.8 ± 15.0
AUC: Metabolite (dFdU) on Day 22 (n=2,2,2,2,2,10)190952.6 ± 9.3376280.5 ± 13.0217930.8 ± 70.4327424.8 ± 2.0248496.4 ± 5.2247430.7 ± 29.2
SecondarySafety Run-In Part: Apparent Oral Clearance (CL/f) of Pimasertib (MSC1936369B): Regimen 1

Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) was influenced by the fraction of the dose absorbed.

Time frame:
0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1, 22 of Cycle 1
Reported as:
Geometric mean · Liter per hour (L/h)
Safety Run-In Part: Apparent Oral Clearance (CL/f) of Pimasertib (MSC1936369B): Regimen 1
Liter per hour (L/h)Regimen 1:15 mgRegimen 1: 30 mgRegimen 1: 45 mgRegimen 1: 68 mgRegimen 1: 90 mgRegimen 1: 120 mg
CL/f: MSC1936369B on Day 1 (n=4,3,3,2,3,11)92.152 ± 25.358.104 ± 32.951.072 ± 37.187.765 ± 58.952.025 ± 32.355.171 ± 53.0
CL/f: MSC1936369B on Day 22 (n=2,2,3,2,3,9)74.143 ± 43.642.484 ± 31.244.579 ± 23.156.502 ± 7.550.873 ± 59.655.723 ± 57.8
SecondarySafety Run-In Part: Total Clearance (CL) of Gemcitabine: Regimen 1

Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.

Time frame:
0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1, 22 of Cycle 1
Reported as:
Geometric mean · liter/hour
Safety Run-In Part: Total Clearance (CL) of Gemcitabine: Regimen 1
liter/hourRegimen 1: 15 mgRegimen 1: 30 mgRegimen 1: 45 mgRegimen 1: 68 mgRegimen 1: 90 mgRegimen 1: 120 mg
CL: Gemcitabine on Day 1 (n=4,3,3,3,3,11)60.537 ± 483.4133.88 ± 45.1190.52 ± 26.095.96 ± 47.7210.25 ± 27.9151.93 ± 54.7
CL: Gemcitabine on Day 22 (n=2,2,1,2,2,9)163.37 ± 93.7156.93 ± 20.1190.69 ± NA25.123 ± 431.2183.97 ± 11.6164.6 ± 71.7
SecondarySafety Run-In Part: Oral Volume of Distribution (V/f) of Pimasertib (MSC1936369B): Regimen 1

Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.

Time frame:
0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1, 22 of Cycle 1
Reported as:
Geometric mean · liter
Safety Run-In Part: Oral Volume of Distribution (V/f) of Pimasertib (MSC1936369B): Regimen 1
literRegimen 1: 15 mgRegimen 1: 30 mgRegimen 1: 45 mgRegimen 1: 68 mgRegimen 1: 90 mgRegimen 1: 120 mg
V/f: MSC1936369B on Day 1 (n=4,3,3,2,3,11)528.62 ± 63.1369.12 ± 5.0329.80 ± 28.4524.96 ± 26.2362.29 ± 34.0367.25 ± 50.5
V/f: MSC1936369B on Day 22 (n=2,2,3,2,3,8)824.33 ± 156.8366.30 ± 1.8264.31 ± 43.8441.40 ± 43.4284.42 ± 35.1414.38 ± 66.8
SecondarySafety Run-In Part: Apparent Volume of Distribution (V) of Gemcitabine: Regimen 1

Apparent volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.

Time frame:
0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1, 22 of Cycle 1
Reported as:
Geometric mean · liter
Safety Run-In Part: Apparent Volume of Distribution (V) of Gemcitabine: Regimen 1
literRegimen 1: 15 mgRegimen 1: 30 mgRegimen 1: 45 mgRegimen 1: 68 mgRegimen 1: 90 mgRegimen 1: 120 mg
V: Gemcitabine (dFdC) on Day 1 (n= 4,3,3,3,3,11)359.55 ± 635.6531.23 ± 64.7587.64 ± 206.3729.65 ± 46.32402.1 ± 59.51270.1 ± 82.0
V: Gemcitabine (dFdC) on Day 22 (n=2,2,1,2,2,9)1723.6 ± 55.9908.50 ± 56.5251.79 ± NA149.65 ± 1453.72140.8 ± 15.5805.15 ± 138.0
SecondarySafety Run-In Part: Levels of Pharmacodynamic (Pd) Markers (Phosphorylated- Extracellular Signal-Regulated Kinase (ERK) in Peripheral Blood Mononuclear Cells [PBMCs]): Regimen 1

ERK phosphoprotein in peripheral blood monocytes (PBMCs) was analyzed from blood samples of all subjects in the SAF analysis set (safety-run part) only.

Time frame:
pre-dose on Day 1, 2, 22 of Cycle 1; post-dose on Day 1, 22 of Cycle 1
Reported as:
Mean · Fluorescence Intensity
Safety Run-In Part: Levels of Pharmacodynamic (Pd) Markers (Phosphorylated- Extracellular Signal-Regulated Kinase (ERK) in Peripheral Blood Mononuclear Cells [PBMCs]): Regimen 1
Fluorescence IntensityRegimen 1:15 mgRegimen 1: 30 mgRegimen 1: 45 mgRegimen 1: 68 mgRegimen 1: 90 mgRegimen1: 120 mg
Cycle 1 Day 1 Pre-dose (n=3,2,2,3,3,7)5.389 ± 0.7976.476 ± 0.9974.767 ± 0.1146.509 ± 2.2404.608 ± 0.1974.229 ± 1.719
Cycle 1 Day 1 Post-dose (n=3,2,2,3,2,6)1.611 ± 0.5372.061 ± 0.8250.837 ± 0.1493.881 ± 5.3871.059 ± 0.0420.946 ± 0.248
Cycle 1 Day 2 Pre-dose (n=3,2,1,2,2,6)4.818 ± 0.8086.719 ± 2.8353.902 ± NA2.768 ± 0.3304.874 ± 2.1193.636 ± 1.755
Cycle 1 Day 22 Pre-dose (n=2,1,2,1,3,5)5.242 ± 0.2106.000 ± NA1.978 ± 2.5398.653 ± NA4.252 ± 1.2593.453 ± 0.860
Cycle 1 Day 22 Post-dose (n=0,0,0,0,2)NA ± NANA ± NANA ± NANA ± NANA ± NA4.130 ± 1.772
SecondarySafety Run-In Part: Maximum Concentration (Cmax) of Pimasertib (MSC1936369B), Gemcitabine (dFdC), Gemcitabine Inactive Metabolite 2',2'-Difluorodeoxyuridine (dFdU): Regimen 2
Time frame:
0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1, 22 of Cycle 1
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Safety Run-In Part: Maximum Concentration (Cmax) of Pimasertib (MSC1936369B), Gemcitabine (dFdC), Gemcitabine Inactive Metabolite 2',2'-Difluorodeoxyuridine (dFdU): Regimen 2
nanogram per milliliter (ng/mL)Regimen 2: 60 mgRegimen 2: 75 mg
MSC1936369B on Day 1 (n= 12,13)175.7 ± 65.0345.5 ± 52.8
MSC1936369B on Day 22 (n=10,9)228.2 ± 59.0244.8 ± 31.9
Gemcitabine (dFdC) on Day 1 (n=11,14)27849.2 ± 344.017663.9 ± 173.3
Gemcitabine (dFdC) on Day 22 (n=9,4)21589.7 ± 118.818733.4 ± 88.6
Gemcitabine Metabolite (dFdU) on Day 1 (n=11, 10)33033.3 ± 11.831623.9 ± 25.4
Gemcitabine Metabolite (dFdU) on Day 22 (n=10,5)13455.5 ± 546.018298.7 ± 247.7
SecondarySafety Run-In Part: Area Under Curve (AUC:0 to Infinity) of Pimasertib (MSC1936369B), Gemcitabine (dFdC), and Gemcitabine Inactive Metabolite 2',2'-Difluorodeoxyuridine (dFdU) Regimen 2

AUC:0 to infinity is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption.

Time frame:
0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1 of Cycle 1 for MSC1936369B, 0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1, 22 of Cycle 1 for Gemcitabine
Reported as:
Geometric mean · hour*nanogram per milliliter (h*ng/mL)
Safety Run-In Part: Area Under Curve (AUC:0 to Infinity) of Pimasertib (MSC1936369B), Gemcitabine (dFdC), and Gemcitabine Inactive Metabolite 2',2'-Difluorodeoxyuridine (dFdU) Regimen 2
hour*nanogram per milliliter (h*ng/mL)Regimen 2: 60 mgRegimen 1: 75 mg
AUC: MSC1936369B on Day 1 (n= 10, 11)704.3 ± 69.41427.0 ± 30.0
AUC: Gemcitabine (dFdC) on Day 1 (n= 11, 14)11932.0 ± 343.08065.5 ± 176.2
AUC: Gemcitabine (dFdC) on Day 22 (n= 9, 4)10719.1 ± 84.910102.3 ± 72.0
AUC: Metabolite (dFdU) on Day 1 (n= 11, 13)189007.0 ± 40.6234934.8 ± 29.9
AUC: Metabolite (dFdU) on Day 22 (n= 10, 5)177504.5 ± 171.5256714.9 ± 37.3
SecondarySafety Run-In Part: Time to Reach Maximum Concentration (Tmax) of Pimasertib (MSC1936369B), Gemcitabine (dFdC), and Gemcitabine Inactive Metabolite 2',2'-Difluorodeoxyuridine (dFdU): Regimen 2
Time frame:
0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1, 22 of Cycle 1
Reported as:
Median · hours
Safety Run-In Part: Time to Reach Maximum Concentration (Tmax) of Pimasertib (MSC1936369B), Gemcitabine (dFdC), and Gemcitabine Inactive Metabolite 2',2'-Difluorodeoxyuridine (dFdU): Regimen 2
hoursRegimen 2: 60 mgRegimen 2: 75 mg
Tmax: MSC1936369B on Day 1 (n=12,13)2.000 (0.50 to 3.98)1.583 (0.50 to 7.98)
Tmax: MSC1936369B on Day 22 (n=10,9)1.500 (0.25 to 4.40)2.000 (0.58 to 4.00)
Tmax: Gemcitabine (dFdC) on Day 1 (n=11,14)0.50 (0.25 to 0.73)0.38 (0.25 to 0.75)
Tmax: Gemcitabine (dFdC) on Day 22 (n=9,4)0.25 (0.00 to 0.50)0.25 (0.25 to 0.50)
Tmax: Metabolite (dFdU) on Day 1 (n=11,13)0.67 (0.50 to 0.75)0.67 (0.25 to 1.00)
Tmax: Metabolite (dFdU) on Day 22 (n=10,5)0.50 (0.00 to 2.00)0.50 (0.50 to 0.75)
SecondarySafety Run-In Part: Time to Reach Apparent Terminal Half-Life (t1/2) of Pimasertib (MSC1936369B), Gemcitabine (dFdC), and Gemcitabine Inactive Metabolite 2',2'-Difluorodeoxyuridine (dFdU): Regimen 2

Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

Time frame:
0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1, 22 of Cycle 1
Reported as:
Median · hours
Safety Run-In Part: Time to Reach Apparent Terminal Half-Life (t1/2) of Pimasertib (MSC1936369B), Gemcitabine (dFdC), and Gemcitabine Inactive Metabolite 2',2'-Difluorodeoxyuridine (dFdU): Regimen 2
hoursRegimen 2: 60 mgRegimen 2: 75 mg
t1/2: MSC1936369B on Day 1 (n=10,11)2.757 (2.183 to 3.557)2.603 (1.775 to 4.910)
t1/2: MSC1936369B on Day 22 (n=8,5)3.425 (2.584 to 10.60)3.188 (2.296 to 4.617)
t1/2: Gemcitabine (dFdC) on Day 1 (n=11,14)5.258 (0.796 to 8.757)5.376 (0.6681 to 11.64)
t1/2: Gemcitabine (dFdC) on Day 22 (n=9,4)5.522 (3.759 to 11.45)5.249 (0.3198 to 9.505)
t1/2: Metabolite (dFdU) on Day 1 (n=11,13)9.471 (6.559 to 13.10)10.26 (7.123 to 12.92)
t1/2: Metabolite (dFdU) on Day 22 (n=10,5)10.68 (6.543 to 441.9)13.58 (7.575 to 17.535)
SecondarySafety Run-In Part: Apparent Oral Clearance (CL/f) of Pimasertib (MSC1936369B): Regimen 2

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.

Time frame:
0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1, 22 of Cycle 1
Reported as:
Geometric mean · Liter per hour (L/H)
Safety Run-In Part: Apparent Oral Clearance (CL/f) of Pimasertib (MSC1936369B): Regimen 2
Liter per hour (L/H)Regimen 2: 60 mgRegimen 2: 75 mg
CL/f: MSC1936369B on Day 1 (n=10,11)85.186 ± 69.452.558 ± 30.0
CL/f: MSC1936369B on Day 22 (n=8,5)70.163 ± 63.268.312 ± 24.9
SecondarySafety Run-In Part: Total Clearance (CL) of Gemcitabine: Regimen 2

Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.

Time frame:
0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1, 22 of Cycle 1
Reported as:
Geometric mean · liter/hour
Safety Run-In Part: Total Clearance (CL) of Gemcitabine: Regimen 2
liter/hourRegimen 2: 60 mgRegimen 2: 75 mg
CL: Gemcitabine on Day 1 (n=11, 14)145.65 ± 363.2221.46 ± 186.0
CL: Gemcitabine on Day 22 (n=9, 4)164.68 ± 81.4183.85 ± 73.5
SecondarySafety Run-In Part: Apparent Volume of Distribution (V) of Gemcitabine: Regimen 2

Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.

Time frame:
0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1, 22 of Cycle 1
Reported as:
Geometric mean · liter
Safety Run-In Part: Apparent Volume of Distribution (V) of Gemcitabine: Regimen 2
literRegimen 2: 60 mgRegimen 2: 75 mg
V: Gemcitabine on Day 1 (n=11,14)716.12 ± 343.31059.0 ± 196.6
V: Gemcitabine on Day 22 (n=9,4)1590.8 ± 120.5801.90 ± 130.3
SecondarySafety Run-In Part: Oral Volume of Distribution (V/f) of Pimasertib (MSC1936369B): Regimen 2

Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.

Time frame:
0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1, 22 of Cycle 1
Reported as:
Geometric mean · liter
Safety Run-In Part: Oral Volume of Distribution (V/f) of Pimasertib (MSC1936369B): Regimen 2
literRegimen 2: 60 mgRegimen 2: 75 mg
V/f: MSC1936369B on Day 1 (n= 10,11)335.56 ± 66.3213.24 ± 37.7
V/f: MSC1936369B on Day 22 (n=8,5)389.56 ± 47.1319.02 ± 35.5
SecondarySafety Run-In Part: Levels of Pharmacodynamic (Pd) Markers (Phosphorylated- Extracellular Signal-Regulated Kinase (ERK) in Peripheral Blood Mononuclear Cells [PBMCs]): Regimen 2

ERK phosphoprotein in peripheral blood monocytes (PBMCs) was analyzed from blood samples of all subjects in the SAF analysis set (safety-run part) only.

Time frame:
pre-dose on Day 1, 2, 22 of Cycle 1; post-dose on Day 1, 22 of Cycle 1
Reported as:
Mean · Fluorescence Intensity
Safety Run-In Part: Levels of Pharmacodynamic (Pd) Markers (Phosphorylated- Extracellular Signal-Regulated Kinase (ERK) in Peripheral Blood Mononuclear Cells [PBMCs]): Regimen 2
Fluorescence IntensityRegimen 2: 60 mgRegimen 2: 75 mg
Cycle 1 Day 1 Pre-dose (n=7,4)6.081 ± 0.8275.874 ± 2.239
Cycle 1 Day 1 Post-dose (n=5,3)1.520 ± 0.1091.048 ± 0.155
Cycle 1 Day 2 Pre-dose (n=7,3)3.877 ± 2.0992.263 ± 0.593
Cycle 1 Day 22 Pre-dose (n=6,2)2.728 ± 0.8182.295 ± 0.510
Cycle 1 Day 22 Post-dose (n=3,1)1.443 ± 0.4581.111 ± NA
SecondaryPhase II: Number of Subjects With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Leading to Permanent Treatment Discontinuation

An AE was any untoward medical occurrence in a subject who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. All AEs (serious and non-serious) except AEs recorded with an onset date prior to the first day of drug administration unless a worsening of the event was recorded after the first dosing date, in which case the event was counted as a TEAE. TEAEs include both SAEs and non-SAEs.

Time frame:
From the first dose of study drug administration until EOT (6 years)
Reported as:
Number · subjects
Phase II: Number of Subjects With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Leading to Permanent Treatment Discontinuation
subjectsPhase II: Arm 1Phase II: Arm 2
TEAEs4045
Serious TEAEs2835
TEAEs Leading to Treatment Discontinuation1021
SecondaryPhase II: Percentage of Subjects With Best Overall Response (BOR)

Best overall response was defined as the presence of at least one complete response (CR), partial response (PR) or Stable Disease (SD) (using RECIST v1.0) during treatment. CR: Disappearance of all target lesions, PR: At least 30% decrease in the sum of the longest diameter of target lesions, taking as reference the sum of the longest diameter at baseline and SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of the longest diameter since treatment started.

Time frame:
Baseline, every 8 weeks up to end of treatment (EOT i.e. 6 years)
Reported as:
Number · percentage of subjects
Phase II: Percentage of Subjects With Best Overall Response (BOR)
percentage of subjectsPhase II: Arm 1Phase II: Arm 2
CR00
PR9.19.1
SD36.450.0
PD29.520.5
Missing2520.5
SecondaryPhase II: Percentage of Subjects With Clinical Benefit

Clinical Benefit was defined as the presence of at least one CR, PR or Stable Disease (SD) (using RECIST v1.0) during treatment. CR: Disappearance of all target lesions, PR: At least 30% decrease in the sum of the longest diameter of target lesions, taking as reference the sum of the longest diameter at baseline and SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of the longest diameter since treatment started.

Time frame:
Baseline, every 8 weeks up to end of treatment (EOT i.e. 6 years)
Reported as:
Number · percentage of subjects
Phase II: Percentage of Subjects With Clinical Benefit
percentage of subjectsPhase II: Arm 1Phase II: Arm 2
Phase II: Percentage of Subjects With Clinical Benefit45.559.1
SecondaryPhase II: Time to Progression (TTP)

Time to progression (TTP) is defined as the time (in months) from the randomization date to the date of progression prior to the start of any subsequent therapy for the primary disease, as reported and documented by the Investigator (i.e. radiological progression per RECIST).

Time frame:
From randomization every 8 weeks up to EOT (6 years)
Reported as:
Median · months
Phase II: Time to Progression (TTP)
monthsPhase II: Arm 1Phase II: Arm 2
Phase II: Time to Progression (TTP)3.78 (1.87 to 5.55)5.09 (3.75 to 6.47)
SecondaryPhase II: Overall Survival (OS) Time

Overall survival (OS) time is defined as the time (in months) from randomization to death.

Time frame:
Baseline, every 8 weeks up to EOT (6 years)
Reported as:
Median · months
Phase II: Overall Survival (OS) Time
monthsPhase II: Arm 1Phase II: Arm 2
Phase II: Overall Survival (OS) Time6.64 (5.06 to NA)9.33 (3.71 to NA)
SecondaryPhase II: Absorption Rate Constant (ka) of Pimasertib (MSC1936369B)
Time frame:
Baseline, every 8 weeks up to EOT (6 years)

No measurements were reported for this outcome.

SecondaryPhase II: Clearance From Central Compartment (CL/f) and Intercompartmental Clearance (Q/f) of Pimasertib (MSC1936369B)
Time frame:
Baseline, every 8 weeks up to EOT (6 years)

No measurements were reported for this outcome.

SecondaryPhase II: Volume of Central Compartment (V1/f) and Volume of Peripheral Compartment (V2/f) of Pimasertib (MSC1936369B)
Time frame:
Baseline, every 8 weeks up to EOT (6 years)

No measurements were reported for this outcome.

Adverse events

Collected over From the first dose of study drug administration until EOT (6 years). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Safety Run-in Part: Regimen 1—18/27 (66.7%)27/27 (100%)
Safety Run-in Part: Regimen 2—20/26 (76.9%)26/26 (100%)
Phase II: Arm 1—28/42 (66.7%)39/42 (92.9%)
Phase II: Arm 2—35/45 (77.8%)44/45 (97.8%)
Most frequent serious events
Showing 10 of 130
Most frequent serious events
EventSafety Run-in Part: Regimen 1Safety Run-in Part: Regimen 2Phase II: Arm 1Phase II: Arm 2
PyrexiaGeneral disorders2/276/265/425/45
Disease progressionGeneral disorders1/270/265/424/45
CholangitisHepatobiliary disorders3/271/262/422/45
OverdoseInjury, poisoning and procedural complications0/271/263/425/45
DyspnoeaRespiratory, thoracic and mediastinal disorders3/271/260/421/45
VomitingGastrointestinal disorders0/271/264/424/45
Blood bilirubin increasedInvestigations0/270/264/420/45
ThrombocytopeniaBlood and lymphatic system disorders2/271/260/424/45
Retinal Vein OcclusionEye disorders0/272/260/420/45
Retinal detachmentEye disorders0/272/261/421/45
Most frequent other events
Showing 10 of 345
Most frequent other events
EventSafety Run-in Part: Regimen 1Safety Run-in Part: Regimen 2Phase II: Arm 1Phase II: Arm 2
DiarrhoeaGastrointestinal disorders14/2719/268/4220/45
ThrombocytopeniaBlood and lymphatic system disorders17/2713/269/4216/45
NauseaGastrointestinal disorders16/2715/2615/4223/45
Oedema peripheralGeneral disorders14/2715/268/4222/45
FatigueGeneral disorders15/275/2617/4217/45
Retinal detachmentEye disorders10/2714/261/4210/45
NeutropeniaBlood and lymphatic system disorders14/276/2617/4217/45
PyrexiaGeneral disorders14/2711/2612/4217/45
AstheniaGeneral disorders8/2713/266/429/45
VomitingGastrointestinal disorders13/2712/2611/4222/45

Baseline characteristics

The safety analysis set (SAF) analysis set for the safety run-in part included subjects who received at least 1 (non-zero) administration of trial medication (pimasertib or gemcitabine). For Phase II: Intention-to-treat (ITT) set included subjects who were randomized, as per Interactive Voice Response System (IVRS).

Age, Categorical
Age, Categorical(Participants)Safety Run-in Part: Regimen 1Safety Run-in Part: Regimen 2Phase II: Arm 1 (Gemcitabine + Placebo)Phase II: Arm 2 (Gemcitabine + Pimasertib)Total
<=18 years00000
Between 18 and 65 years1619252888
>=65 years117191653
Sex: Female, Male
Sex: Female, Male(Participants)Safety Run-in Part: Regimen 1Safety Run-in Part: Regimen 2Phase II: Arm 1 (Gemcitabine + Placebo)Phase II: Arm 2 (Gemcitabine + Pimasertib)Total
Female98221756
Male1818222785
08

Study locations

2 sites
  • For Recruiting Locations in the United States, please Contact U.S. Medical Information
    Rockland, Massachusetts, United States
  • For Recruiting Locations outside the United States, Please contact the Merck KGaA Communication Center
    Darmstadt, Germany
09

References and documents

Publications

  • Van Cutsem E, Hidalgo M, Canon JL, Macarulla T, Bazin I, Poddubskaya E, Manojlovic N, Radenkovic D, Verslype C, Raymond E, Cubillo A, Schueler A, Zhao C, Hammel P. Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer. Int J Cancer. 2018 Oct 15;143(8):2053-2064. doi: 10.1002/ijc.31603. Epub 2018 Aug 9. PubMed 29756206 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2009 to primary completion in Dec 2013, 49 months.

Results were first posted in Jun 2017, 3 years 5 months after primary completion.

Of 195 industry-sponsored phase 1/2 interventional studies under Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 88. This study's 49 months is below that.

Counting every sponsor, half of 297 studies reached it within 60 months; a quarter within 39 and three quarters within 89.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2009
First posted
Nov 19, 2009
StartActual
Nov 30, 2009
Primary completionActual
Dec 31, 2013
CompletionActual
Apr 30, 2015
Results first posted
Jun 23, 2017
Last update
Jul 13, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01016483
Lead sponsor
EMD Serono
Responsible party
Sponsor
First posted
Nov 19, 2009
Start date
Nov 30, 2009
Primary completion
Dec 31, 2013
Completion
Apr 30, 2015
Results posted
Jun 23, 2017
Last update
Jul 13, 2017

Study contacts

Medical Responsible
study director · Merck KGaA, Darmstadt, Germany

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pimasertib

Start the discussion